Verve Therapeutics (VERV) Financials

$4.43 -0.17 (-3.70%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$4.46 +0.04 (+0.79%)

As of 05/30/2025 07:20 PM Eastern

Annual Income Statements for Verve Therapeutics

This table shows Verve Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-199	-200	-157
Consolidated Net Income / (Loss)	-199	-200	-157
Net Income / (Loss) Continuing Operations	-199	-200	-157
Total Pre-Tax Income	-198	-200	-157
Total Operating Income	-229	-223	-166
Total Gross Profit	32	12	1.94
Total Revenue	32	12	1.94
Operating Revenue	32	12	1.94
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	261	235	168
Selling, General & Admin Expense	57	50	38
Research & Development Expense	204	185	130
Total Other Income / (Expense), net	30	23	8.35
Other Income / (Expense), net	30	23	8.35
Income Tax Expense	0.35	0.28	0.05
Basic Earnings per Share	($2.35)	($3.12)	($2.91)
Weighted Average Basic Shares Outstanding	84.72M	64.18M	54.02M
Diluted Earnings per Share	($2.35)	($3.12)	($2.91)
Weighted Average Diluted Shares Outstanding	84.72M	64.18M	54.02M
Weighted Average Basic & Diluted Shares Outstanding	88.80M	83.62M	61.83M

This table shows Verve Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-52	-48	-50	-49	-48	-46	-55	-52	-41	-45
Consolidated Net Income / (Loss)	-50	-50	-50	-49	-48	-46	-54	-52	-41	-45
Net Income / (Loss) Continuing Operations	-50	-50	-50	-49	-48	-46	-54	-52	-41	-45
Total Pre-Tax Income	-50	-50	-50	-49	-48	-46	-54	-52	-41	-45
Total Operating Income	-56	-57	-59	-57	-54	-52	-59	-58	-48	-44
Total Gross Profit	13	6.87	6.69	5.70	5.14	3.12	2.09	1.40	1.01	0.93
Total Revenue	13	6.87	6.69	5.70	5.14	3.12	2.09	1.40	1.01	0.93
Operating Revenue	13	6.87	6.69	5.70	5.14	3.12	2.09	1.40	1.01	0.93
Total Operating Expenses	69	64	66	63	59	55	61	60	49	45
Selling, General & Admin Expense	14	14	15	14	12	12	13	13	11	9.59
Research & Development Expense	55	50	51	48	47	44	47	47	37	35
Total Other Income / (Expense), net	6.11	6.88	9.10	8.21	5.63	6.64	4.78	6.28	6.68	-1.33
Other Income / (Expense), net	6.11	6.88	9.10	8.21	5.63	6.64	4.78	6.28	6.68	-1.33
Income Tax Expense	0.07	0.10	0.07	0.11	0.03	0.07	0.18	0.00	-	0.00
Basic Earnings per Share	($0.58)	($0.59)	($0.59)	($0.59)	($0.69)	($0.72)	($0.87)	($0.84)	($0.66)	($0.79)
Weighted Average Basic Shares Outstanding	84.72M	84.63M	84.23M	83.13M	64.18M	63.21M	61.95M	61.79M	54.02M	57.21M
Diluted Earnings per Share	($0.58)	($0.59)	($0.59)	($0.59)	($0.69)	($0.72)	($0.87)	($0.84)	($0.66)	($0.79)
Weighted Average Diluted Shares Outstanding	84.72M	84.63M	84.23M	83.13M	64.18M	63.21M	61.95M	61.79M	54.02M	57.21M
Weighted Average Basic & Diluted Shares Outstanding	88.80M	84.66M	84.62M	83.97M	83.62M	63.75M	63.72M	61.93M	61.83M	61.60M

This table details how cash moves in and out of Verve Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-34	91	51
Net Cash From Operating Activities	-158	-150	-122
Net Cash From Continuing Operating Activities	-158	-150	-122
Net Income / (Loss) Continuing Operations	-199	-200	-157
Consolidated Net Income / (Loss)	-199	-200	-157
Depreciation Expense	6.75	5.46	2.80
Amortization Expense	-12	-14	-1.03
Non-Cash Adjustments To Reconcile Net Income	49	42	25
Changes in Operating Assets and Liabilities, net	-2.26	18	8.38
Net Cash From Investing Activities	75	28	-156
Net Cash From Continuing Investing Activities	75	28	-156
Purchase of Property, Plant & Equipment	-3.74	-9.28	-13
Purchase of Investments	-424	-517	-479
Sale and/or Maturity of Investments	503	554	337
Net Cash From Financing Activities	49	213	329
Net Cash From Continuing Financing Activities	49	213	329
Repurchase of Common Equity	-0.07	-0.46	-0.78
Issuance of Common Equity	48	212	328
Other Financing Activities, net	1.26	1.20	2.18

This table details how cash moves in and out of Verve Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	14	17	-2.71	-62	128	8.28	-14	-32	-162	204
Net Cash From Operating Activities	-41	-40	-34	-43	-41	-12	-48	-49	-33	-29
Net Cash From Continuing Operating Activities	-41	-40	-34	-43	-41	-12	-48	-49	-33	-29
Net Income / (Loss) Continuing Operations	-50	-50	-50	-49	-48	-46	-54	-52	-41	-45
Consolidated Net Income / (Loss)	-50	-50	-50	-49	-48	-46	-54	-52	-41	-45
Depreciation Expense	1.70	1.75	1.67	1.63	1.52	1.47	1.34	1.13	0.93	0.72
Amortization Expense	-2.16	-2.75	-3.54	-3.97	-3.34	-3.49	-3.70	-3.86	-2.14	-0.12
Non-Cash Adjustments To Reconcile Net Income	12	13	12	12	12	9.75	11	8.92	6.85	9.82
Changes in Operating Assets and Liabilities, net	-2.85	-1.12	5.83	-4.12	-2.22	26	-2.98	-3.31	2.56	5.60
Net Cash From Investing Activities	30	57	30	-42	-8.89	-12	33	15	-168	-56
Net Cash From Continuing Investing Activities	30	57	30	-42	-8.89	-12	33	15	-168	-56
Purchase of Property, Plant & Equipment	-1.39	-0.94	-0.98	-0.43	-2.19	-1.06	-2.66	-3.38	-4.97	-2.64
Purchase of Investments	-73	-75	-112	-164	-122	-148	-113	-134	-257	-148
Sale and/or Maturity of Investments	104	133	143	123	116	137	149	153	94	95
Net Cash From Financing Activities	25	0.01	1.30	23	177	32	1.23	2.04	40	288
Net Cash From Continuing Financing Activities	25	0.01	1.30	23	177	32	1.23	2.04	40	288
Issuance of Common Equity	25	-	0.42	22	178	32	0.62	1.99	39	288
Other Financing Activities, net	0.12	0.01	0.83	0.30	0.32	0.21	0.55	0.12	0.44	1.11

This table presents Verve Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	647	753	679
Total Current Assets	543	638	563
Cash & Equivalents	173	206	115
Short-Term Investments	352	418	439
Prepaid Expenses	15	8.10	7.34
Other Current Assets	3.26	5.90	1.01
Plant, Property, & Equipment, net	19	23	19
Total Noncurrent Assets	86	92	97
Long-Term Investments	0.00	0.00	0.00
Other Noncurrent Operating Assets	86	92	97
Total Liabilities & Shareholders' Equity	647	753	679
Total Liabilities	154	153	128
Total Current Liabilities	43	37	35
Accounts Payable	4.52	6.64	2.42
Accrued Expenses	24	20	21
Current Deferred Revenue	3.61	0.00	-
Other Current Liabilities	10	10	-
Total Noncurrent Liabilities	111	116	93
Noncurrent Deferred Revenue	50	49	20
Other Noncurrent Operating Liabilities	61	68	73
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	493	600	551
Total Preferred & Common Equity	493	600	551
Preferred Stock	0.00	0.00	0.00
Total Common Equity	493	600	551
Common Stock	1,236	1,144	896
Retained Earnings	-743	-544	-344
Accumulated Other Comprehensive Income / (Loss)	0.43	0.27	-0.69

This table presents Verve Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	664	701	732	612	589	634	673
Total Current Assets	556	591	620	498	473	518	562
Cash & Equivalents	159	141	144	78	70	84	277
Short-Term Investments	381	434	462	407	392	425	274
Prepaid Expenses	14	12	8.19	9.89	8.50	7.70	9.99
Other Current Assets	2.63	3.04	5.77	3.15	2.09	1.40	0.93
Plant, Property, & Equipment, net	20	20	21	21	21	21	15
Total Noncurrent Assets	88	90	91	93	95	96	97
Other Noncurrent Operating Assets	88	90	91	93	95	96	97
Total Liabilities & Shareholders' Equity	664	701	732	612	589	634	673
Total Liabilities	155	155	149	152	124	125	125
Total Current Liabilities	43	40	31	35	33	34	29
Accounts Payable	4.64	6.83	3.05	1.05	3.15	3.37	0.47
Accrued Expenses	22	20	17	23	20	19	20
Current Deferred Revenue	5.72	3.48	1.47	-	-	-	-
Other Current Liabilities	10	10	10	10	10	11	8.90
Total Noncurrent Liabilities	113	114	118	117	91	91	96
Noncurrent Deferred Revenue	51	51	52	49	20	20	20
Other Noncurrent Operating Liabilities	62	63	66	69	71	71	76
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	509	546	583	460	465	509	548
Total Preferred & Common Equity	509	546	583	460	465	509	548
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	509	546	583	460	465	509	548
Common Stock	1,200	1,190	1,177	957	916	906	852
Retained Earnings	-693	-643	-593	-496	-450	-396	-303
Accumulated Other Comprehensive Income / (Loss)	1.14	-0.62	-0.50	-0.60	-0.75	-0.24	-0.92

This table displays calculated financial ratios and metrics derived from Verve Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	174.98%	505.77%	0.00%
EBITDA Growth	2.26%	-34.18%	-32.65%
EBIT Growth	0.72%	-26.99%	-30.77%
NOPAT Growth	-2.48%	-34.67%	-90.30%
Net Income Growth	0.68%	-27.12%	-30.81%
EPS Growth	24.68%	-7.22%	35.04%
Operating Cash Flow Growth	-5.45%	-22.25%	-57.08%
Free Cash Flow Firm Growth	-24.18%	2.67%	-84.96%
Invested Capital Growth	-26.31%	-404.53%	359.81%
Revenue Q/Q Growth	32.53%	54.18%	108.93%
EBITDA Q/Q Growth	-0.14%	-3.93%	-8.45%
EBIT Q/Q Growth	-0.83%	-3.79%	-6.57%
NOPAT Q/Q Growth	-0.94%	-2.88%	-10.08%
Net Income Q/Q Growth	-0.85%	-3.77%	-6.60%
EPS Q/Q Growth	4.47%	-0.97%	-153.99%
Operating Cash Flow Q/Q Growth	-0.10%	-5.49%	-4.13%
Free Cash Flow Firm Q/Q Growth	-1.03%	4.64%	0.00%
Invested Capital Q/Q Growth	1.56%	1.65%	390.13%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-630.99%	-1,775.13%	-8,014.27%
Operating Margin	-707.23%	-1,897.64%	-8,536.17%
EBIT Margin	-613.51%	-1,699.21%	-8,105.82%
Profit (Net Income) Margin	-614.59%	-1,701.55%	-8,108.55%
Tax Burden Percent	100.18%	100.14%	100.03%
Interest Burden Percent	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-4,697.48%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-4,688.32%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	4,662.83%
Return on Equity (ROE)	-36.36%	-34.78%	-34.66%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-1,583.20%
Operating Return on Assets (OROA)	-28.34%	-27.91%	-29.59%
Return on Assets (ROA)	-28.39%	-27.94%	-29.60%
Return on Common Equity (ROCE)	-36.36%	-34.78%	-34.66%
Return on Equity Simple (ROE_SIMPLE)	-40.27%	-33.37%	-28.57%
Net Operating Profit after Tax (NOPAT)	-160	-156	-116
NOPAT Margin	-495.06%	-1,328.35%	-5,975.32%
Net Nonoperating Expense Percent (NNEP)	-6.73%	-7.52%	-9.17%
Return On Investment Capital (ROIC_SIMPLE)	-32.44%	-26.05%	-20.61%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	175.20%	424.70%	1,933.69%
R&D to Revenue	632.03%	1,572.94%	6,702.47%
Operating Expenses to Revenue	807.23%	1,997.64%	8,636.17%
Earnings before Interest and Taxes (EBIT)	-198	-200	-157
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-204	-209	-156
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.97	1.48	2.16
Price to Tangible Book Value (P/TBV)	0.97	1.48	2.16
Price to Revenue (P/Rev)	14.77	75.58	614.13
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	80.86
Enterprise Value to Revenue (EV/Rev)	0.00	22.52	334.43
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.02
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.05	-1.01	-0.99
Leverage Ratio	1.28	1.24	1.17
Compound Leverage Factor	1.28	1.24	1.17
Debt to Total Capital	0.00%	0.00%	2.12%
Short-Term Debt to Total Capital	0.00%	0.00%	2.12%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	97.89%
Debt to EBITDA	0.00	0.00	-0.08
Net Debt to EBITDA	0.00	0.00	3.49
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	-0.10
Net Debt to NOPAT	0.00	0.00	4.68
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	0.22	2.57	5.04
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	12.65	17.24	16.05
Quick Ratio	12.22	16.86	15.81
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-154	-124	-127
Operating Cash Flow to CapEx	-4,220.88%	-1,611.00%	-924.52%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.05	0.02	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	1.57	0.57	0.15
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-31	-24	8.03
Invested Capital Turnover	-1.17	-1.43	0.79
Increase / (Decrease) in Invested Capital	-6.43	-32	11
Enterprise Value (EV)	-47	265	649
Market Capitalization	478	889	1,192
Book Value per Share	$5.83	$9.40	$8.94
Tangible Book Value per Share	$5.83	$9.40	$8.94
Total Capital	493	600	563
Total Debt	0.00	0.00	12
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-524	-624	-543
Capital Expenditures (CapEx)	3.74	9.28	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-24	-23	-15
Debt-free Net Working Capital (DFNWC)	500	601	540
Net Working Capital (NWC)	500	601	528
Net Nonoperating Expense (NNE)	39	44	41
Net Nonoperating Obligations (NNO)	-524	-624	-543
Total Depreciation and Amortization (D&A)	-5.65	-8.93	1.78
Debt-free, Cash-free Net Working Capital to Revenue	-75.59%	-195.67%	-764.55%
Debt-free Net Working Capital to Revenue	1,545.97%	5,110.93%	27,819.06%
Net Working Capital to Revenue	1,545.97%	5,110.93%	27,205.77%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.35)	($3.12)	($2.91)
Adjusted Weighted Average Basic Shares Outstanding	84.72M	64.18M	54.02M
Adjusted Diluted Earnings per Share	($2.35)	($3.12)	($2.91)
Adjusted Weighted Average Diluted Shares Outstanding	84.72M	64.18M	54.02M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	88.80M	83.62M	61.83M
Normalized Net Operating Profit after Tax (NOPAT)	-160	-156	-116
Normalized NOPAT Margin	-495.06%	-1,328.35%	-5,975.32%
Pre Tax Income Margin	-613.51%	-1,699.21%	-8,105.82%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.03%	-0.23%	-0.50%

This table displays calculated financial ratios and metrics derived from Verve Therapeutics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	154.28%	120.24%	219.73%	305.63%	408.30%	235.52%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-0.55%	-6.94%	8.11%	6.83%	-18.68%	-7.00%	-41.13%	-89.14%	-40.24%	-103.38%
EBIT Growth	-3.40%	-9.49%	7.56%	6.44%	-17.76%	-1.11%	-31.41%	-72.30%	-30.94%	-98.65%
NOPAT Growth	-3.93%	-8.74%	-0.44%	2.43%	-13.07%	-19.32%	-38.85%	-82.49%	-46.62%	-86.62%
Net Income Growth	-3.48%	-9.56%	7.74%	6.23%	-17.69%	-1.26%	-31.84%	-72.30%	-31.11%	-98.65%
EPS Growth	15.94%	18.06%	32.18%	29.76%	-4.55%	8.86%	-3.57%	-35.48%	-108.64%	-68.09%
Operating Cash Flow Growth	-0.41%	-235.34%	28.78%	12.25%	-23.68%	59.52%	-79.24%	-46.52%	-17.29%	-36.62%
Free Cash Flow Firm Growth	-520.58%	-129.14%	78.57%	51.00%	88.12%	54.85%	11.81%	-0.55%	0.00%	-164.53%
Invested Capital Growth	-26.31%	-26.20%	-1,187.18%	-3,052.85%	-404.53%	-798.34%	-25.36%	-91.71%	359.81%	35.27%
Revenue Q/Q Growth	90.53%	2.59%	17.51%	10.71%	65.03%	48.93%	49.07%	38.74%	8.93%	0.00%
EBITDA Q/Q Growth	1.18%	1.14%	-1.27%	-1.64%	-5.10%	15.06%	-2.67%	-29.48%	5.25%	-12.04%
EBIT Q/Q Growth	0.13%	-0.58%	-2.28%	-0.64%	-5.75%	15.08%	-3.52%	-26.67%	9.20%	-10.36%
NOPAT Q/Q Growth	1.48%	3.28%	-3.51%	-5.37%	-3.08%	10.67%	-0.56%	-22.11%	-8.78%	-3.95%
Net Income Q/Q Growth	0.20%	-0.66%	-2.19%	-0.79%	-5.67%	15.24%	-3.86%	-26.51%	9.08%	-10.36%
EPS Q/Q Growth	1.69%	0.00%	0.00%	14.49%	4.17%	17.24%	-3.57%	-27.27%	16.46%	5.95%
Operating Cash Flow Q/Q Growth	-3.13%	-15.95%	20.71%	-5.90%	-244.42%	75.37%	2.31%	-49.26%	-12.74%	-9.03%
Free Cash Flow Firm Q/Q Growth	1.53%	-288.07%	45.32%	-196.99%	63.64%	63.71%	-25.05%	28.01%	-38.20%	29.12%
Invested Capital Q/Q Growth	1.56%	-5.07%	-28.14%	4.70%	1.65%	-1,005.21%	248.04%	-90.17%	390.13%	-175.21%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-385.45%	-743.19%	-771.22%	-894.91%	-974.75%	-1,530.64%	-2,683.52%	-3,896.23%	-4,174.70%	-4,799.78%
Operating Margin	-428.65%	-828.99%	-879.24%	-998.14%	-1,048.76%	-1,678.99%	-2,799.00%	-4,149.50%	-4,714.43%	-4,721.21%
EBIT Margin	-381.97%	-728.75%	-743.26%	-853.91%	-939.35%	-1,465.86%	-2,570.81%	-3,701.92%	-4,054.55%	-4,864.37%
Profit (Net Income) Margin	-382.53%	-730.27%	-744.25%	-855.77%	-939.97%	-1,468.01%	-2,579.22%	-3,701.92%	-4,059.78%	-4,864.37%
Tax Burden Percent	100.15%	100.21%	100.13%	100.22%	100.07%	100.15%	100.33%	100.00%	100.13%	100.00%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3,316.63%	-1,884.42%	-2,594.37%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3,313.19%	-1,881.72%	-2,592.66%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3,285.24%	1,858.65%	2,578.57%	0.00%
Return on Equity (ROE)	-36.36%	-40.67%	-38.10%	-36.03%	-34.78%	-38.24%	-31.39%	-25.77%	-15.80%	-31.65%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4,512.23%	-2,437.56%	-1,583.20%	0.00%
Operating Return on Assets (OROA)	-17.64%	-27.86%	-23.79%	-20.05%	-15.43%	-17.39%	-30.61%	-25.18%	-14.80%	-8.34%
Return on Assets (ROA)	-17.67%	-27.92%	-23.82%	-20.10%	-15.44%	-17.41%	-30.71%	-25.18%	-14.82%	-8.34%
Return on Common Equity (ROCE)	-36.36%	-40.67%	-38.10%	-36.03%	-34.78%	-38.24%	-31.39%	-25.77%	-15.80%	-31.65%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-38.74%	-35.28%	-33.76%	0.00%	-41.88%	-41.32%	-35.17%	0.00%	-26.94%
Net Operating Profit after Tax (NOPAT)	-39	-40	-41	-40	-38	-37	-41	-41	-33	-31
NOPAT Margin	-300.05%	-580.29%	-615.47%	-698.70%	-734.13%	-1,175.29%	-1,959.30%	-2,904.65%	-3,300.10%	-3,304.84%
Net Nonoperating Expense Percent (NNEP)	-1.88%	-2.01%	-1.66%	-1.60%	-1.81%	-1.76%	-3.44%	-2.70%	-1.70%	-3.08%
Return On Investment Capital (ROIC_SIMPLE)	-7.95%	-	-	-	-6.30%	-	-	-	-5.93%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	107.78%	201.56%	217.38%	248.69%	238.74%	374.91%	640.99%	894.09%	1,130.34%	1,032.51%
R&D to Revenue	420.86%	727.43%	761.86%	849.45%	910.01%	1,404.07%	2,258.00%	3,355.41%	3,684.09%	3,788.70%
Operating Expenses to Revenue	528.65%	928.99%	979.24%	1,098.14%	1,148.76%	1,778.99%	2,899.00%	4,249.50%	4,814.43%	4,821.21%
Earnings before Interest and Taxes (EBIT)	-50	-50	-50	-49	-48	-46	-54	-52	-41	-45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-50	-51	-52	-51	-50	-48	-56	-55	-42	-45
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.97	0.81	0.75	1.45	1.48	1.84	2.50	1.75	2.16	3.76
Price to Tangible Book Value (P/TBV)	0.97	0.81	0.75	1.45	1.48	1.84	2.50	1.75	2.16	3.76
Price to Revenue (P/Rev)	14.77	16.79	19.84	52.75	75.58	110.80	213.53	266.56	614.13	2,216.38
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	254.45	485.36	80.86	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	14.97	22.52	47.17	128.49	114.48	334.43	1,623.58
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.05	-1.06	-1.03	-1.02	-1.01	-1.03	-0.99	-0.99	-0.99	-1.01
Leverage Ratio	1.28	1.32	1.28	1.25	1.24	1.28	1.20	1.17	1.17	1.16
Compound Leverage Factor	1.28	1.32	1.28	1.25	1.24	1.28	1.20	1.17	1.17	1.16
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.12%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.12%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	97.89%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.08	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.49	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.10	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.68	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.98	0.84	1.04	3.04	3.23	2.88	5.16	4.06	5.60	9.95
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	12.65	13.05	14.64	19.82	17.24	14.41	14.32	15.43	16.05	19.35
Quick Ratio	12.22	12.66	14.27	19.38	16.86	14.03	14.00	15.16	15.81	18.98
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-33	-33	-8.59	-16	-5.29	-15	-40	-32	-45	-32
Operating Cash Flow to CapEx	-2,944.85%	-4,231.52%	-3,485.51%	-9,949.65%	-1,861.78%	-1,113.20%	-1,801.73%	-1,454.70%	-662.08%	-1,106.37%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.05	0.04	0.03	0.02	0.02	0.01	0.01	0.01	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.57	1.21	1.00	0.76	0.57	0.42	0.32	0.21	0.15	0.09
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-31	-31	-30	-23	-24	-25	2.75	0.79	8.03	-2.77
Invested Capital Turnover	-1.17	-0.87	-1.52	-1.43	-1.43	-0.55	1.69	0.65	0.79	-0.26
Increase / (Decrease) in Invested Capital	-6.43	-6.51	-33	-24	-32	-22	-0.93	-8.73	11	1.51
Enterprise Value (EV)	-47	-130	-166	240	265	360	699	383	649	1,508
Market Capitalization	478	410	410	847	889	845	1,161	892	1,192	2,059
Book Value per Share	$5.83	$6.01	$6.50	$7.01	$9.40	$7.22	$7.51	$8.24	$8.94	$9.14
Tangible Book Value per Share	$5.83	$6.01	$6.50	$7.01	$9.40	$7.22	$7.51	$8.24	$8.94	$9.14
Total Capital	493	509	546	583	600	460	465	509	563	548
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	12	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-524	-540	-576	-606	-624	-485	-462	-509	-543	-551
Capital Expenditures (CapEx)	1.39	0.94	0.98	0.43	2.19	1.06	2.66	3.38	4.97	2.64
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-24	-26	-25	-17	-23	-22	-22	-24	-15	-18
Debt-free Net Working Capital (DFNWC)	500	514	551	589	601	464	440	484	540	533
Net Working Capital (NWC)	500	514	551	589	601	464	440	484	528	533
Net Nonoperating Expense (NNE)	11	10	8.62	8.95	11	9.12	13	11	7.69	14
Net Nonoperating Obligations (NNO)	-524	-540	-576	-606	-624	-485	-462	-509	-543	-551
Total Depreciation and Amortization (D&A)	-0.46	-0.99	-1.87	-2.34	-1.82	-2.02	-2.36	-2.73	-1.22	0.60
Debt-free, Cash-free Net Working Capital to Revenue	-75.59%	-107.00%	-123.15%	-108.01%	-195.67%	-282.45%	-412.67%	-731.00%	-764.55%	-1,948.12%
Debt-free Net Working Capital to Revenue	1,545.97%	2,106.15%	2,666.21%	3,670.21%	5,110.93%	6,080.33%	8,091.85%	14,476.38%	27,819.06%	57,331.75%
Net Working Capital to Revenue	1,545.97%	2,106.15%	2,666.21%	3,670.21%	5,110.93%	6,080.33%	8,091.85%	14,476.38%	27,205.77%	57,331.75%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.58)	($0.59)	($0.59)	($0.59)	($0.69)	($0.72)	($0.87)	($0.84)	($0.66)	($0.79)
Adjusted Weighted Average Basic Shares Outstanding	84.72M	84.63M	84.23M	83.13M	64.18M	63.21M	61.95M	61.79M	54.02M	57.21M
Adjusted Diluted Earnings per Share	($0.58)	($0.59)	($0.59)	($0.59)	($0.69)	($0.72)	($0.87)	($0.84)	($0.66)	($0.79)
Adjusted Weighted Average Diluted Shares Outstanding	84.72M	84.63M	84.23M	83.13M	64.18M	63.21M	61.95M	61.79M	54.02M	57.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	88.80M	84.66M	84.62M	83.97M	83.62M	63.75M	63.72M	61.93M	61.83M	61.60M
Normalized Net Operating Profit after Tax (NOPAT)	-39	-40	-41	-40	-38	-37	-41	-41	-33	-31
Normalized NOPAT Margin	-300.05%	-580.29%	-615.47%	-698.70%	-734.13%	-1,175.29%	-1,959.30%	-2,904.65%	-3,300.10%	-3,304.84%
Pre Tax Income Margin	-381.97%	-728.75%	-743.26%	-853.91%	-939.35%	-1,465.86%	-2,570.81%	-3,701.92%	-4,054.55%	-4,864.37%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.03%	0.00%	-0.24%	-0.23%	-0.23%	0.00%	0.00%	-0.47%	-0.50%	-0.41%

Frequently Asked Questions About Verve Therapeutics' Financials

When does Verve Therapeutics's financial year end?

According to the most recent income statement we have on file, Verve Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Verve Therapeutics' net income changed over the last 2 years?

Verve Therapeutics' net income appears to be on an upward trend, with a most recent value of -$198.71 million in 2024, rising from -$157.39 million in 2022. The previous period was -$200.07 million in 2023. Find out what analysts predict for Verve Therapeutics in the coming months.

What is Verve Therapeutics's operating income?

Verve Therapeutics's total operating income in 2024 was -$228.66 million, based on the following breakdown:

Total Gross Profit: $32.33 million
Total Operating Expenses: $260.99 million

How has Verve Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Verve Therapeutics' total revenue changed from $1.94 million in 2022 to $32.33 million in 2024, a change of 1,565.7%.

How much debt does Verve Therapeutics have?

Verve Therapeutics' total liabilities were at $153.99 million at the end of 2024, a 0.5% increase from 2023, and a 20.0% increase since 2022.

How much cash does Verve Therapeutics have?

In the past 2 years, Verve Therapeutics' cash and equivalents has ranged from $115.41 million in 2022 to $206.18 million in 2023, and is currently $172.56 million as of their latest financial filing in 2024.

How has Verve Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Verve Therapeutics' book value per share changed from 8.94 in 2022 to 5.83 in 2024, a change of -34.8%.

Related Companies

This page (NASDAQ:VERV) was last updated on 6/1/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verve Therapeutics (VERV) Financials

Frequently Asked Questions About Verve Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verve Therapeutics (VERV) Financials

Annual Income Statements for Verve Therapeutics

Quarterly Income Statements for Verve Therapeutics

Annual Cash Flow Statements for Verve Therapeutics

Quarterly Cash Flow Statements for Verve Therapeutics

Annual Balance Sheets for Verve Therapeutics

Quarterly Balance Sheets for Verve Therapeutics

Annual Metrics And Ratios for Verve Therapeutics

Quarterly Metrics And Ratios for Verve Therapeutics

Frequently Asked Questions About Verve Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools